Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma

Yasuyuki Mizutani(Nagoya University), Mitsuhiro Fujishiro(Bunkyo University), Eizaburo Ohno(Nagoya University), Tadashi Iida(Nagoya University), Miwa Imai(Nagoya University Hospital), Hiroki Kawashima(Nagoya University Hospital), Fumie Kinoshita(Nagoya University Hospital), Yachiyo Kuwatsuka(Nagoya University Hospital), Takuya Ishikawa(Nagoya University), Shinobu Shimizu(Nagoya University Hospital), Toshihisa Tsuruta(Nagoya University Hospital), Atsushi Enomoto(Nagoya University)
BMC Cancer
February 24, 2022
Cited by 32


Related Papers